Full-Time

Head of Biotherapeutics – Sr. Director or VP Level

Confirmed live in the last 24 hours

Manifold Bio

Manifold Bio

11-50 employees

Designs precision biologics using in vivo methods

Biotechnology
Healthcare

Senior, Expert

Boston, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech

You match the following Manifold Bio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Experience taking multiple molecules through IND and into the clinic
  • Deep understanding of protein production techniques, including mammalian cell culture and purification/characterization approaches
  • Expertise in novel biotherapeutic modalities, across a range of formats
  • Extensive experience leading cross-functional teams
  • Experience with complex biologics (e.g. multispecifics)
Responsibilities
  • Leading internal protein sciences and protein engineering teams
  • Own strategy for early stage de-risking and optimization of lead molecules
  • Own strategy for developability assessment
  • Work with internal and external team members to ensure cost-effective and timely drug manufacture
  • Build internal expertise on cutting-edge protein engineering techniques
  • Guide prioritization for internal protein generation efforts, balancing between screening and lead characterization
  • Build an R&D-to-development pipeline for lead candidates
  • Utilize state of the art techniques to drive the development of best-in-class therapeutic candidates
  • Stay up to speed on cutting edge research and industry standards for protein therapeutics
Desired Qualifications
  • Experience with drug development in neuroscience
  • Experience liaising with CDMOs through IND
  • Experience with generative AI models for protein design

Manifold Bio focuses on creating precision biologics for the pharmaceutical industry. Their main product is an in vivo drug design platform, which allows for drug testing within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment. This is particularly beneficial for testing complex biologics, which are large molecule drugs derived from living organisms. Unlike other companies, Manifold Bio's approach to drug design is the first of its kind, emphasizing in vivo testing. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Company Size

11-50

Company Stage

Series A

Total Funding

$58.8M

Headquarters

Boston, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $40M in Series A funding, indicating strong market interest.
  • Their platform could revolutionize in vivo testing by testing multiple molecules simultaneously.
  • Strategic partnerships with multiple investors enhance growth and development opportunities.

What critics are saying

  • Increased competition from companies like Insamo and Infinimmune.
  • Rapid AI and ML advancements may outpace Manifold Bio's current technology.
  • Regulatory challenges in in vivo testing could delay product development timelines.

What makes Manifold Bio unique

  • Manifold Bio uses proprietary mCodes™ technology for protein multiplexing in drug design.
  • Their in vivo drug design platform is the first of its kind globally.
  • The company specializes in precision biologics, focusing on complex biologics development.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

0%
Swanson Reed
Apr 19th, 2024
Manifold Bio Secues $15M in Series A Funding

Manifold Bio secues $15M in Series A funding.

Business Wire
Feb 28th, 2024
Playground Global Promotes Benjamin Kim Phd To Partner

PALO ALTO, Calif.--(BUSINESS WIRE)--Playground Global, an early-stage, deep-tech venture firm that invests in founders building category-defining businesses at the forefront of science and technology, today announced that Benjamin Kim PhD, has been promoted to Partner. Ben focuses on identifying founders and companies that are revolutionizing engineered biology, building the future of emerging modality therapeutics development, and unlocking AI and ML workflows to refactor drug development. Ben joined Playground as a Venture Fellow in 2019 while completing his PhD in bioengineering at Stanford University. He became a Venture Associate a year later, and by 2022, he had led investments in two breakthrough biotech companies and was promoted to Venture Principal. In the last year, Ben has supported investments in Insamo (Board Observer and Lead Investor), Infinimmune (Board Director and Lead Seed Investor), Atomic AI (Board Observer and Lead Series A investor) and Amber Bio (Board Observer and Co-Led Seed Investment Round). He has also worked with Outpace Bio and Manifold Bio, where he is a Board Observer

Finsmes
Jul 14th, 2022
Manifold Bio Raises $40M In Series A Funding

Manifold Bio, a Boston, MA-based protein therapeutics company, raised $40M in Series A funding. The round was led by Triatomic Capital with participation from Section 32, FPV Ventures, Horizons Ventures, Tencent, Playground Global, Fifty Years, and FAST. With this funding, Triatomic Capital founding partner Jeff Huber will join Manifold Bio’s board of directors. Huber was previously founder and CEO of Grail and co-founder of Google’s life sciences efforts

Business Wire
Jul 14th, 2022
Horizons Ventures invested into manifold.bio in $40M on Jul 14th 22'.

Manifold Bio, a next-generation protein therapeutics company pioneering an in vivo biologics design platform, today announced the close of a $40 million Series A financing round led by Triatomic Capital and joined by new investors Section 32, FPV Ventures, Horizons Ventures, and Tencent.

TechCrunch
Jul 14th, 2022
Manifold Bio’S Molecular ‘Barcodes’ Could Break Through Pharma’S In Vivo Bottleneck

In the creation of a new drug, there comes a point where you have to finally put the molecule in a real creature — one at a time — and see if it actually does what you think it does. Manifold Bio’s molecular machinery could let a hundred molecules be tested simultaneously in a single living system, potentially upending the whole process. The drug discovery space has advanced a lot in the last few years, first with fast and cheap gene transcription, then with CRISPR, then with AI-powered proteomics. You don’t have to know what all of those do, however, to understand that in the end, no matter how much they accelerate fundamental research, in vivo testing remains a major bottleneck

Torch Security
Jul 14th, 2022
Manifold Bio receives financing of $40M

Manifold Bio, a new startup founded by one of Boston’s most prolific biotech entrepreneurs, has raised $40 million to develop a technology that could make testing cancer drugs more efficient.

Intelligence360
Jul 4th, 2022
Allston Massachusetts Based Manifold Bio Is Raising $39,999,985.00 In New Equity Investment.

Allston, MA – According to filings with the U.S. Securities and Exchange Commission, Manifold Bio is raising $39,999,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gleb Kuznetsov played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Manifold Bio

Business Wire
Sep 8th, 2020
Manifold Bio Raises Seed Round to Bring Massively Multiplexed Measurement to Drug Discovery

Manifold Bio raises seed round to bring massively multiplexed measurement to drug discovery.